These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3743619)

  • 1. Fluocortolone: pharmacokinetics and effect on plasma cortisol level.
    Täuber U; Richter K; Matthes H
    Eur J Clin Pharmacol; 1986; 30(4):433-8. PubMed ID: 3743619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.
    Tüber U; Posern U; Bickel U; Matthes H; Voigt K
    Eur J Clin Pharmacol; 1988; 35(2):177-81. PubMed ID: 2847930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of fluocortolone in long term therapy of patients with rheumatic and hematologic diseases].
    Lopatta F; Vecsei P; Täuber U; Haack D
    Arzneimittelforschung; 1986 Aug; 36(8):1268-71. PubMed ID: 3490855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)].
    Gleispach H; Porta S
    Wien Klin Wochenschr; 1981 Nov; 93(21):671-3. PubMed ID: 7324480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.
    Täuber U; Haack D; Nieuweboer B; Kloss G; Vecsei P; Wendt H
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):48-55. PubMed ID: 6698661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of fluocortolone in man.
    Legler UF
    Eur J Clin Pharmacol; 1986; 30(5):615-7. PubMed ID: 3758149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone.
    Rohatagi S; Täuber U; Richter K; Derendorf H
    J Clin Pharmacol; 1996 Apr; 36(4):311-4. PubMed ID: 8728344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic modeling of cortisol suppression from fluocortolone.
    Lew KH; Jusko WJ
    Eur J Clin Pharmacol; 1993; 45(6):581-3. PubMed ID: 8157047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Binding of cortisol, fluocortolone and difluocortolone to human plasma proteins (author's transl)].
    Fellier H; Gleispach H; Esterbauer H
    J Clin Chem Clin Biochem; 1977 Oct; 15(10):545-8. PubMed ID: 925615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of topical glucocorticoids on endogenous cortisol production].
    Neumann RA; Schmidt JB; Spona J
    Z Hautkr; 1988 Apr; 63(4):302-8. PubMed ID: 3291439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal sleep in humans.
    Born J; Zwick A; Roth G; Fehm-Wolfsdorf G; Fehm HL
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):129-37. PubMed ID: 3661052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of impairment of fluocortolone disposition in oral contraceptive users.
    Legler UF
    Eur J Clin Pharmacol; 1988; 35(1):101-3. PubMed ID: 3220090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent pharmacokinetics of dexamethasone.
    Loew D; Schuster O; Graul EH
    Eur J Clin Pharmacol; 1986; 30(2):225-30. PubMed ID: 3709651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial.
    Werumeus Buning J; Touw DJ; Brummelman P; Dullaart RPF; van den Berg G; van der Klauw MM; Kamp J; Wolffenbuttel BHR; van Beek AP
    Metabolism; 2017 Jun; 71():7-16. PubMed ID: 28521880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Charmandari E; Johnston A; Brook CG; Hindmarsh PC
    J Endocrinol; 2001 Apr; 169(1):65-70. PubMed ID: 11250647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary-adrenal and pituitary-thyroid function during administration of difluocortolone and dexamethasone to human subjects.
    Lambe RF; O'Kelly DA; Darragh A
    Ir J Med Sci; 1978 Jan; 147(1):15-25. PubMed ID: 632057
    [No Abstract]   [Full Text] [Related]  

  • 19. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler.
    Grahnén A; Jansson B; Brundin RM; Ling-Andersson A; Lönnebo A; Johansson M; Eckernäs SA
    Eur J Clin Pharmacol; 1997; 52(4):261-7. PubMed ID: 9248762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations.
    Hindmarsh PC; Charmandari E
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):557-61. PubMed ID: 25369980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.